DELFI Diagnostics

DELFI Diagnostics is a biotechnology and healthcare startup based in the United States, founded in 2019. The company's slogan, "Saving lives through early cancer detection," reflects its core mission. DELFI leverages artificial intelligence and whole genome sequencing to sensitively detect unique patterns of DNA fragmentation in the blood of patients with cancer. In its most recent funding round, the company secured a significant $225.00M Series B investment on 18 July 2022. The impressive list of investors participating in this round includes OrbiMed, Osage University Partners, T. Rowe Price, Brown Advisory, Cowen Digital, Foresite Capital, Northpond Ventures, PTX Capital, Rock Springs Capital, and Point Field Partners. DELFI Diagnostics is poised to revolutionize the field of cancer detection and treatment through its innovative approach, making it a compelling prospect for venture capital investment.